Journal
MINI-REVIEWS IN MEDICINAL CHEMISTRY
Volume 10, Issue 11, Pages 1058-1070Publisher
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/1389557511009011058
Keywords
Anticancer; cancer; CDKIs; combination therapy; flavopiridol; flavonoid
Categories
Funding
- National Natural Science Foundation of China [30973622]
Ask authors/readers for more resources
The cell cycle is the series of events necessary for the division and duplication of a cell. The dysregulation of the cell cycle can promote the development of cancer. A group of proteins, cyclin-dependent kinases (CDKs), that control the cell cycle, provide new targets for treating cancer. As a result, cyclin-dependent kinase inhibitors (CDKIs) represent a novel class of chemotherapeutic agents. Of these, flavopiridol, a semisynthetic flavonoidal alkaloid, emerged as the first CDKI to enter clinical trials. Preclinical data indicate that flavopiridol could block the proliferation of neoplastic cells and induce programmed cell death as a single agent. Furthermore, recent emerging data revealed that flavopiridol can potentiate, generally in a dose-and sequence-dependent manner, the anti-tumor effects of many established chemotherapeutic agents. This review is primarily focused on the role of flavopiridol in combination with various therapeutic agents that are in or near clinical development.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available